<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413762</url>
  </required_header>
  <id_info>
    <org_study_id>IREC019</org_study_id>
    <nct_id>NCT02413762</nct_id>
  </id_info>
  <brief_title>The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London Diabetes Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London Diabetes Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the potential of the gut hormones GLP-1, PP, PYY and the iron
      regulatory hormone hepcidin as biomarkers for progression to complications in diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron overload and mechanisms inducing insulin resistance are reciprocally linked. Dietary
      iron absorption, and iron uptake in liver and adipose tissue, are regulated through the
      hormone hepcidin. Iron is implicated in microvascular and macrovascular disease pathways and
      therefore hepcidin may represent a biomarker for progression to complications in type 2
      diabetes mellitus.

      Serum pancreatic polypeptide levels correlate with visceral adiposity and may therefore
      contribute to the diagnosis of, and risk stratification in, the metabolic syndrome.

      Hypothesis:

      Measuring iron status, incretin hormones and serum pancreatic polypeptide will facilitate
      discrimination of patients at risk of vascular complications of T2DM and clinically
      significant non-alcoholic fatty liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular complications of diabetes mellitus</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to NAFLD or NASH</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>NGT, no insulin resistance</arm_group_label>
    <description>Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFG/IGT/T2DM</arm_group_label>
    <description>Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin resistance without IGT</arm_group_label>
    <description>e.g. polycystic ovarian syndrome. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGT, no insulin resistance</arm_group_label>
    <description>e.g. T1DM. No intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Previous metabolic surgery</arm_group_label>
    <description>Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Previous metabolic surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults resident in the UAE, attending ICLDC for normal healthcare.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all

        Exclusion Criteria:

          -  lack of capacity for informed consent; vulnerable individuals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nader Lessan, MBBS FRCP MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London Diabetes Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nader Lessan, MBBS FRCP MD</last_name>
    <phone>+971 2 404 0800</phone>
    <email>nlessan@icldc.ae</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam J Buckley, MRCP MRes</last_name>
    <phone>+971 2 404 0800</phone>
    <phone_ext>504</phone_ext>
    <email>abuckley@icldc.ae</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College London Diabetes Centre</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>48338</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nader Lessan, MBBS MD FRCP</last_name>
      <phone>+971 2 404 0800</phone>
      <email>nlessan@icldc.ae</email>
    </contact>
    <contact_backup>
      <last_name>Adam J Buckley, MRCP MRes</last_name>
      <phone>+971 2 404 0800</phone>
      <phone_ext>504</phone_ext>
      <email>abuckley@icldc.ae</email>
    </contact_backup>
    <investigator>
      <last_name>Nader Lessan, MBBS MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adam J Buckley, MRCP MRes</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <reference>
    <citation>Sam AH, Sleeth ML, Thomas EL, Ismail NA, Mat Daud N, Chambers E, Shojaee-Moradie F, Umpleby M, Goldstone AP, Le Roux CW, Bech P, Busbridge M, Laurie R, Cuthbertson DJ, Buckley A, Ghatei MA, Bloom SR, Frost GS, Bell JD, Murphy KG. Circulating pancreatic polypeptide concentrations predict visceral and liver fat content. J Clin Endocrinol Metab. 2015 Mar;100(3):1048-52. doi: 10.1210/jc.2014-3450. Epub 2014 Dec 9.</citation>
    <PMID>25490276</PMID>
  </reference>
  <reference>
    <citation>Sam AH, Busbridge M, Amin A, Webber L, White D, Franks S, Martin NM, Sleeth M, Ismail NA, Daud NM, Papamargaritis D, Le Roux CW, Chapman RS, Frost G, Bloom SR, Murphy KG. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med. 2013 Dec;30(12):1495-9. doi: 10.1111/dme.12262. Epub 2013 Aug 19.</citation>
    <PMID>23796160</PMID>
  </reference>
  <reference>
    <citation>Fleming RE. Iron and inflammation: cross-talk between pathways regulating hepcidin. J Mol Med (Berl). 2008 May;86(5):491-4. doi: 10.1007/s00109-008-0349-8.</citation>
    <PMID>18425494</PMID>
  </reference>
  <reference>
    <citation>Fargion S, Dongiovanni P, Guzzo A, Colombo S, Valenti L, Fracanzani AL. Iron and insulin resistance. Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:61-3.</citation>
    <PMID>16225476</PMID>
  </reference>
  <reference>
    <citation>Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P, Soos MA, Carpenter TA, Lomas DJ, Cochran EK, Gorden P, O'Rahilly S, Savage DB. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009 Feb;119(2):315-22. doi: 10.1172/JCI37432. Epub 2009 Jan 26.</citation>
    <PMID>19164855</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Hepcidins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

